Q/C Technologies Reworks Preferred Share and Warrant Terms in Deal With PharmaCyte
Q/C Technologies agreed with PharmaCyte Biotech to amend Series G and H preferred shares, and the Series H maturity moves to September 2, 2027.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Q/C Technologies has changed the terms of its Series G and Series H preferred shares and certain warrants under an agreement with PharmaCyte Biotech. PharmaCyte owns most of both preferred series. The revisions cover the procedure for future amendments and limits on beneficial ownership.
PharmaCyte also consented to pushing the Series H maturity from March 2, 2027 to September 2, 2027. The maturity amendment was filed on November 20, 2026, according to TradingView.
why it matters
For markets, this is a routine disclosure from a small company, and its broader impact is minimal. The changes concern capital structure and the maturity dates of preferred securities, not the company's operating results.
tags
instruments
sources
- Q/C Technologies Amends Series G and H Preferred Stock and Warrant Terms With PharmaCyte — TradingView, 20 November 2026 at 22:23 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗